Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anticoagulants and Bleeding Disorders Clear all
Not listed No phase listed Observational

Safety of Oral Anticoagulants Registry

NCT02745054
View directory record Official record
Conditions
Blood Coagulation
Interventions
mgt of bleeding concerns/complications of oral anticoagulants
Other
Lead sponsor
Hospital Quality Foundation
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
9
States / cities
Birmingham, Alabama • Hartford, Connecticut • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 27, 2026, 9:34 PM EDT
Withdrawn No phase listed Observational

Safety and Efficacy of Apixaban in Severe Renal Impairment

NCT03399305
View directory record Official record
Conditions
Renal Disease, End Stage, Anticoagulant-induced Bleeding
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 27, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

NCT02740335
View directory record Official record
Conditions
Significant Bleeding Risk
Interventions
Octaplex, Beriplex P/N (Kcentra)
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 27, 2026, 9:34 PM EDT
Active, not recruiting Not applicable Interventional

Amplatzer Amulet LAAO vs. NOAC

NCT04226547
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 27, 2026, 9:34 PM EDT
Recruiting Phase 4 Interventional

International Care Bundle Evaluation in Cerebral Hemorrhage Research

NCT06429332
View directory record Official record
Conditions
Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions
Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care
Other · Diagnostic Test
Lead sponsor
Region Skane
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 27, 2026, 9:34 PM EDT
Completed Not applicable Interventional

LEAVE Safe With DOACs

NCT04068727
View directory record Official record
Conditions
Cardiovascular Diseases, Venous Thromboembolism, Atrial Fibrillation, Bleeding, Stroke
Interventions
Clinical Pharmacist Intervention
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 27, 2026, 9:34 PM EDT
Enrolling by invitation Phase 4 Interventional

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

NCT03244020
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases, Venous Thromboembolism, Hematoma, Anticoagulant-induced Bleeding
Interventions
Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2,868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 27, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

NCT00708435
View directory record Official record
Conditions
Blood Coagulation Disorders, Acute Major Bleeding
Interventions
Beriplex® P/N (Kcentra), Fresh frozen plasma
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Franciso, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 27, 2026, 9:34 PM EDT
Completed No phase listed Observational

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

NCT04394234
View directory record Official record
Conditions
Uterine Hemorrhage
Interventions
Direct oral anticoagulant (DOACs), Warfarin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
961,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 27, 2026, 9:34 PM EDT
Withdrawn Phase 4 Interventional

Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy

NCT00377091
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 27, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor

NCT03661528
View directory record Official record
Conditions
Acute Intracranial Hemorrhage
Interventions
andexanet alfa, Usual Care
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Fort Lauderdale, Florida • Augusta, Georgia • Royal Oak, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 27, 2026, 9:34 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 27, 2026, 9:34 PM EDT
Completed No phase listed Observational

Geriatric Head Trauma Short Term Outcomes Project

NCT04044924
View directory record Official record
Conditions
Head Injury, Anticoagulant-induced Bleeding, Fall
Interventions
Not listed
Lead sponsor
Florida Atlantic University
Other
Eligibility
65 Years and older
Enrollment
5,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Delray Beach, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 27, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

NCT00618098
View directory record Official record
Conditions
Reversal of Anticoagulant Treatment
Interventions
Octaplex (human prothrombin complex concentrate), Fresh frozen plasma
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 27, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Results available

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

NCT03864406
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cobicistat, Darunavir/Cobicistat, Rivaroxaban
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 27, 2026, 9:34 PM EDT
Active, not recruiting Not applicable Interventional

Shared Decision for Drug Interactions in Oral Anticoagulation

NCT06401863
View directory record Official record
Conditions
Anticoagulants, Drug Interactions
Interventions
Shared Decision Making Tool
Other
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older
Enrollment
3,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Denver, Colorado • Nashville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 27, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure

NCT00803101
View directory record Official record
Conditions
Reversal of Coagulopathy
Interventions
Beriplex® P/N (Kcentra), Fresh frozen plasma
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Newark, Delaware • Lexington, Kentucky • Boston, Massachusetts + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2015 · Synced Sep 27, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants

NCT01511939
View directory record Official record
Conditions
Osteoarthritis of the Knee, Coagulopathy
Interventions
Pennsaid
Drug
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 27, 2026, 9:34 PM EDT
Completed No phase listed Observational

Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

NCT00788736
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Burlington, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 27, 2026, 9:34 PM EDT
Completed Not applicable Interventional Results available

Strategies for Anticoagulation During Venovenous ECMO

NCT04997265
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism
Interventions
Low intensity anticoagulation, Moderate Intensity Anticoagulation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 27, 2026, 9:34 PM EDT
Terminated Phase 3 Interventional

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

NCT05171049
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Abelacimab, Apixaban
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Aurora, Colorado • West Haven, Connecticut • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 27, 2026, 9:34 PM EDT
Completed Not applicable Interventional Results available

Comparing TR Band to Statseal in Conjunction With TR Band

NCT03028025
View directory record Official record
Conditions
Arterial Occlusion, Angina Pectoris, Cardiovascular Diseases, Atherosclerosis, Hematoma, Anticoagulant-Induced Bleeding, Coronary Artery Disease
Interventions
StatSeal, TR Band
Device
Lead sponsor
VA Long Beach Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 27, 2026, 9:34 PM EDT
Not yet recruiting Phase 3 Interventional

Restarting Anticoagulation After Traumatic Intracranial Hemorrhage

NCT04229758
View directory record Official record
Conditions
Hemorrhage, Intracranial Hemorrhages, Bleeding, Trauma
Interventions
Anticoagulants
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 27, 2026, 9:34 PM EDT
Completed No phase listed Observational Results available

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

NCT04681482
View directory record Official record
Conditions
Atrial Fibrillation, Obesity, Anticoagulants
Interventions
Apixaban
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
107,383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 27, 2026, 9:34 PM EDT